Previous studies have shown that PKM2 can act as one of the downstream transcriptional coactivators of EGF/EGFR signal transduction, which promotes disease progression in glioma cells and it might be upregulated through the EGFR-dependent NF-kB activation [23, 24]. This evidence concerns the gene EGFR and glioma.